EBITDA Margin % is calculated as EBITDA divided by its Revenue. GlycoNex's EBITDA for the
three
months ended in Dec. 2025 was NT$-67.84 Mil. GlycoNex's Revenue for the
three
months ended in Dec. 2025 was NT$4.41 Mil. Therefore, GlycoNex's EBITDA margin for the quarter that ended in Dec. 2025 was -1,540.09%.
GlycoNex (ROCO:4168) EBITDA Margin % Explanation
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
GlycoNex EBITDA Margin % Related Terms
GlycoNex EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for GlycoNex's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ROCO:4168 vs VRTX, REGN, ALNY: EBITDA Margin % Comparison
For the Biotechnology subindustry, GlycoNex's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
GlycoNex EBITDA Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, GlycoNex's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where GlycoNex's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
GlycoNex (ROCO:4168) has a EBITDA Margin % of -1,540.09% as of Dec. 2025. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on GlycoNex and its competitors. According to the industry distribution chart, GlycoNex ranks #673 out of 942 companies in the Biotechnology industry, placing it in the top 71.4%.
Is GlycoNex's EBITDA Margin % too high?
GlycoNex's current EBITDA Margin % is -1,540.09%. Based on the distribution chart, GlycoNex ranks #673 out of 942 companies in the Biotechnology industry, which is below the industry midpoint. Overall, GlycoNex has a GF Score™ of 56/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does GlycoNex's EBITDA Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, GlycoNex ranks #673 out of 942 companies for EBITDA Margin %. This places GlycoNex in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Biotechnology company?
A good EBITDA Margin % depends on the Biotechnology industry context. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on GlycoNex and its competitors. GlycoNex's current EBITDA Margin % is -1,540.09%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is GlycoNex stock overvalued right now?
Based on GuruFocus' analysis, GlycoNex (ROCO:4168) is currently considered Significantly Undervalued. The stock's GF Value™ is NT$74.21, compared to a current price of NT$25.60 — trading 65.5% below its estimated fair value. The current EBITDA Margin % is -1,540.09%. GlycoNex's overall GF Score™ is 56/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For GlycoNex (ROCO:4168), the current EBITDA Margin % is -1,540.09% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is GlycoNex (ROCO:4168) Overvalued in 2026?
Based on GuruFocus' analysis, GlycoNex stock appears to be undervalued.
The current stock price of NT$25.60 is trading 65.5% below its estimated GF Value™ of NT$74.21.
GuruFocus considers GlycoNex to be Significantly Undervalued.
Key valuation signals for ROCO:4168:
EBITDA Margin %: -1,540.09%
GF Value™: NT$74.21 vs. price of NT$25.60 (65.5% below fair value)
No single metric tells the full story. See the ROCO:4168 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
GlycoNex Inc is a Taiwan-based company engaged in the development of cancer drugs from the combination of glycosphingolipid antigen and human monoclonal antibody technologies. It has a panel of antibodies that targets various carbohydrate antigens. The antibodies are cloned from hybridoma, engineered to improve stability, and can serve as reagents with applications that include ELISA, Western blot, flow cytometry, and TLC immunostaining. The other services provided by the firm include functional evaluation, antibody research, and antibody engineering. It has two reportable segments: antibody new drug, which derives maximum revenue, and exclusive investment. Geographically, the group derives maximum revenue from Taiwan and the rest from Japan.
56GF Score
Get the complete analysis for ROCO:4168
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:4168 has been successfully added to your 
